Results 191 to 200 of about 41,111 (239)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 1964
GRAM-negative bacilli, in particular pseudomonas species, are of increasing concern to the clinician as infectious and therapeutic problems.1 , 2 Accordingly, polymyxin B has grown to singular importance as its utility to the treatment of systemic infections caused by pseudomonas species has been appreciated and exploited.
N M, NORD, P D, HOEPRICH
openaire +2 more sources
GRAM-negative bacilli, in particular pseudomonas species, are of increasing concern to the clinician as infectious and therapeutic problems.1 , 2 Accordingly, polymyxin B has grown to singular importance as its utility to the treatment of systemic infections caused by pseudomonas species has been appreciated and exploited.
N M, NORD, P D, HOEPRICH
openaire +2 more sources
Polymyxin-B-binding sites in the cochlea as demonstrated by polymyxin-B/gold labeling
Histochemistry, 1986A polymyxin-B/bovine-serum-albumin/gold complex was used as a probe to detect the binding sites of polymyxin B on thin sections of cochlea embedded in Spurr's resin. The binding sites were found to be mainly located on the stereocilia, the cuticular plate of hair cells, the head plate of Deiters' cells, the tonofilaments in pillar cells and Deiters ...
M, Tachibana +3 more
openaire +2 more sources
Polymyxin B: similarities to and differences from colistin (polymyxin E)
Expert Review of Anti-infective Therapy, 2007Hospital-acquired infections due to multidrug-resistant gram-negative bacteria constitute major health problems, since the medical community is continuously running out of available effective antibiotics and no new agents are in the pipeline. Polymyxins, a group of antibacterials that were discovered during the late 1940s, represent some of the last ...
Andrea, Kwa +3 more
openaire +2 more sources
2019
Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin).
Maria Helena, Rigatto +2 more
openaire +2 more sources
Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin).
Maria Helena, Rigatto +2 more
openaire +2 more sources
Studies of the biosynthesis of polymyxin B
Biochimica et Biophysica Acta (BBA) - General Subjects, 1968Abstract Polymyxin B, a polypeptide antibiotic produced by Bacillus polymyxa, is synthesized towards the end of the exponential growth phase of the organism. Radioactive diaminobutyric acid is taken up by the cells and incorporated into the antibiotic and into other basic peptides.
openaire +2 more sources
Peptide Antibiotics (Polymyxin B and Polymyxin E)
1978Of the five polymyxins, A, B, C, D and E, originally isolated from a spore-bearing bacillus called variously B. aerosporus and B. polymyxa (Garrod et al., 1973), only two have found clinical usefulness, namely polymyxin B, usually in the form of the sulphate, and polymyxin E (colistin), either as the sulphate or sodium sulphomethate.
A. P. Ball, J. A. Gray, J. McM. Murdoch
openaire +1 more source
Prolonged Treatment with Polymyxin B
New England Journal of Medicine, 1960BECAUSE polymyxin B has significant toxic potentialities its use is sharply circumscribed, and prolonged therapy with it is avoided. This report describes an unusual case in which circumstances necessitated the administration of polymyxin B for almost one year to a patient with a single functioning kidney.
openaire +2 more sources
B‐Cell Activating Properties of Polymyxin B
Scandinavian Journal of Immunology, 1978Polymyxins are known to be inhibitors of certain polyclonal B cell activators such as lipopolysac‐charide and dextransulphate. However, increased specific responses to hapten‐coupled mitogens have been reported after the addition of polymyxins to superoptimal conjugate doses.
C I, Smith, L, Hammarström
openaire +2 more sources
Biochemistry, 2000
The Gram-negative bacterial endotoxin lipopolysaccharide (LPS) is a major inducer of sepsis. The natural cyclic peptide polymyxin B (PMB) is a potent antimicrobial agent, albeit highly toxic, by virtue of its capacity to neutralize the devastating effects of LPS. However, the exact mode of association between PMB and LPS is not clear. In this study, we
H, Tsubery +3 more
openaire +2 more sources
The Gram-negative bacterial endotoxin lipopolysaccharide (LPS) is a major inducer of sepsis. The natural cyclic peptide polymyxin B (PMB) is a potent antimicrobial agent, albeit highly toxic, by virtue of its capacity to neutralize the devastating effects of LPS. However, the exact mode of association between PMB and LPS is not clear. In this study, we
H, Tsubery +3 more
openaire +2 more sources
Contact dermatitis to polymyxin B
Contact Dermatitis, 2008M M, Jiaravuthisan, J G, DeKoven
openaire +2 more sources